Purpura

Summary

Purpura (MONDO:0002610) is a disease and 11 clinical trials. Top therapeutic interventions include calcium carbonate, isatuximab, and rituximab. A subtype of hemorrhagic disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 11

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	purpura
Mondo ID	MONDO:0002610
MeSH	D011693
DOID	DOID:3326
SNOMED CT	387778001
UMLS	C0034150
MedGen	19584
Is cancer (heuristic)	no

Also known as: purpura · purpura (disease)

Data availability: 1 HPO phenotype.

Disease family

This is a subtype of hemorrhagic disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › hematologic disorder › hemorrhagic disease › purpura

Related subtypes (27): inherited bleeding disorder, platelet-type, factor VII deficiency, factor X deficiency, vascular hemostatic disease, congenital factor V deficiency, congenital high-molecular-weight kininogen deficiency, congenital factor XII deficiency, alpha-2-plasmin inhibitor deficiency, hemophilia A, hemophilia B, East Texas bleeding disorder, congenital factor XI deficiency, inherited prekallikrein deficiency, congenital plasminogen activator inhibitor type 1 deficiency, thrombomodulin-related bleeding disorder, congenital vitamin K-dependent coagulation factors deficiency, hemorrhagic disease due to alpha-1-antitrypsin Pittsburgh mutation, multiple sclerosis-ichthyosis-factor VIII deficiency syndrome, congenital factor XIII deficiency, congenital fibrinogen deficiency, combined deficiency of factor V and factor VIII, acquired hemophilia, fetal and neonatal alloimmune thrombocytopenia, hereditary von Willebrand disease, acquired von willebrand syndrome, prothrombin deficiency, hemophilia B leyden

Subtypes (3): purpura fulminans, hyperglobulinemic purpura, thrombocytopenic purpura

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

No approved or late-stage (phase ≥3) drug is indicated for this disease; the following are in earlier-phase trials only.

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Retinol.

Clinical trials & evidence

Clinical trials

Clinical trials: 11.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE3	5
PHASE2	2
Not specified	2
PHASE4	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01910831	PHASE4	COMPLETED	Study to Assess DerMend Moisturizing Bruise Formula in Improving the Appearance of Chronically Aged Forearms and Hands
NCT01506414	PHASE3	COMPLETED	Recombinant Human Thrombopoietin in Combination With Rituximab in Immune Thrombocytopenia (ITP)
NCT01525836	PHASE3	COMPLETED	rhTPO Combining Rituximab Versus Low-dose Rituximab in Management of ITP
NCT01734044	PHASE3	COMPLETED	rhTPO Combining Dexamethasone Versus High-dose Dexamethasone for Initial Treatment of ITP
NCT01734057	PHASE3	WITHDRAWN	Recombinant Human Thrombopoietin (rhTPO) Combining Rituximab Versus High-dose Dexamethasone for Initial Treatment of Primary Immune Thrombocytopenia (ITP)
NCT01882127	PHASE3	WITHDRAWN	All-Trans Retinoic Acid (ATRA) Combining Dexamethasone Versus High-dose Dexamethasone for Initial Treatment of Primary Immune Thrombocytopenia (ITP)
NCT00272610	PHASE2	COMPLETED	Topical Vitamin A Versus Vehicle Cream in the Treatment of Aged Skin
NCT03499808	PHASE2	COMPLETED	S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis
NCT06291415	PHASE1	WITHDRAWN	The Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Adult Subjects With Immune Thrombocytopenia (ITP)
NCT01183910	Not specified	UNKNOWN	A Novel Oral Natural Extract for the Treatment of Senile Purpura
NCT04845113	Not specified	COMPLETED	Idiopathic Purpura Fulminans Associated With Anti-PS Antibodies in Children

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CALCIUM CARBONATE	4	1
ISATUXIMAB	4	1
RITUXIMAB	4	1
SOVLEPLENIB	3	1